P450 oxidoreductase: Genetic polymorphisms and implications for drug metabolism and toxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 4, 2008, Pages 439-452

  Hart, Steven N ^a   Zhong, Xiao Bo ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450 oxidoreductase; Drug metabolism; Genetic polymorphism; Pharmacogenetics; POR; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; APAZIQUONE; CYTOCHROME P450 REDUCTASE; MENADIONE; MITOMYCIN C; PARAQUAT; QUINONE DERIVATIVE; TIRAPAZAMINE;

CATALYSIS; CHEMICAL REACTION; CONGENITAL ADRENAL HYPERPLASIA; CYTOTOXICITY; DRUG METABOLISM; DRUG STRUCTURE; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME LOCALIZATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; METABOLIC ACTIVATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; REVIEW; RISK FACTOR; STEROIDOGENESIS;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METABOLIC DETOXICATION, DRUG; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRODRUGS;

EID: 44349094918     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.4.439     Document Type: Review

References (83)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91
2. Meyer UA. Pharmacogenetics: five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5:669-76
3. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Ann Rev Med 2006;57:119-37
4. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-88
5. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99-111
6. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005;7:97-104
7. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42
8. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9
9. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22
10. De Movais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8
11. Wolf CR, Smith CA, Bishop T, et al. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 1994;4:104-6
12. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526
13. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21
14. Renwick AB, Mistry H, Ball SE, et al. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998;28:337-48
15. Schellens JH, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988;37:2507-10
16. Ingelman-Sundberg M, Nebert DW. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee, 2007 March 27. Available from: URL: www.cypalleles.ki.se/ [Last accessed 10 October 2007]
17. Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metabol Dispos 2004;32:149-54
18. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NRID) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005;6:369-83
19. Ikeda S, Kurose K, Jinno H, et al. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab 2005;86:314-9
20. Lamba J, Strom S, Venkatammanan R, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006;79:325-38
21. Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14:441-52
22. Michalski C, Cui Y, Nies AT, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002;277:43058-63
23. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002;302:804-13
24. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chemi 2001;276:35669-75
25. Horecker B. Triphosphopyridine nucleotide-cytochrome c reductase in liver. J Biol Chem 1950;183:593-605
26. Williams CH Jr, Kamin H. Microsomal triphosphopyridine nucleoride-cytochrome c reductase of liver. J Biol Chem 1962;237:587-95
27. Schacter BA, Nelson EB, Marver HS, Masters BS. Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J Biol Chem 1972;247:5601-7
28. Ono T, Bloch K. Solubilization and partial characterization of rat liver squalene epoxidase. J Biol Chem 1975;250:1571-9
29. Nishino H, Ishibashi T. Evidence for requirement of NADPH-cytochrome P450 oxidoreductase in the microsomal NADPH-sterol Delta7-reductase system. Arch Biochem Biophys 2000;374:293-8
30. Enoch HG, Strittmatter P. Cytochrome b5 reduction by NADPH-cytochrome P-450 reductase. J Biol Chem 1979;254:8976-81
31. Vennilion JL BD, Massey V, Coon MJ. Separate mies for FMN and FAD in catalysis by liver microsomal NADPH-cytochmme P450 reductase. J Biol Chem 1981;256:266-77
32. Guengerich FP, Johnson WW. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. Biochemistry 1997;36:14741-50
33. Hildebrandt A, Estabrook RW. Evidence for the participation of cytochrome b 5 in hepatic microsomal mixed-function oxidation reactions. Arch Biochem Biophys 1971;143:66-79
34. Noshiro M, Ullrich V, Omura T. Cytochrome b5 as electron donor for oxy-cytochrome P450. Eur J Biochem 1981;116:521-6
35. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001;14:611-50
36. Wang M, Roberts DL, Paschke R, et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Nad Acad Sci USA 1997;94:8411-6
37. Hubbard PA, Shen AL, Paschke R, et al. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001;276:29163-70
38. Gutierrez A, Lian LY, Wolf CR, et al. Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains. Biochemistry 2001;40:1964-75
39. Gutierrez A, Paine M, Wolf CR, et al. Relaxation kinetics of cytochrome P450 reductase: internal electron transfer is limited by conformational change and regulated by coenzyme binding. Biochemistry 2002;41:4626-37
40. Grunau A, Paine MJ, Ladbury JE, Gutierrez A. Global effects of the energetics of coenzyme binding: NADPH controls the protein interaction properties of human cytochrome P450 reductase. Biochemistry 2006;45:1421-34
41. Sue Masters B, Marohnic CC. Cytochromes P450: a family of proteins and scientists - understanding their relationships. Drug Metab Rev 2006;38:209-25
42. Gutierrez A, Grunau A, Paine M, et al. Electron transfer in human cytochrome P450 reductase. Biochem Soc Trans 2003;31:497-501
43. Gigon PL, Gram TE, Gillette JR. Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: effect of drug substrates. Mol Pharmacol 1969;5:109-22
44. Ullrich V. On the hydroxylation of cyclohexane in rat liver microsomes. Hoppe Seyler's Zeitschrift fur physiologische Chemie 1969;350:357-65
45. Otto DM, Henderson CJ, Carrie D, et al. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003;23:6103-16
46. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002;277:6536-41
47. Ribes V, Otto DM, Dickmann L, et al. Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Dev Biol 2007;303:66-81
48. Gu J, Weng Y, Zhang QY, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278:25895-901
49. Henderson CJ, Otto DM, Carrie D, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003;278:13480-6
50. Mutch DM, Klocke B, Morrison P, et al. The disruption of hepatic cytochrome P450 reductase alters mouse lipid metabolism. J Proteome Res 2007;6:3976-84
51. Shephard EA, Phillips IR, Santisteban I, et al. Isolation of a human cytochrome P450 reductase cDNA clone and localization of the corresponding gene to chromosome 7ql1.2. Ann Hum Genet 1989;53:291-301
52. Zhao Z, Fu YX, Hewett-Emmett D, Boenvinkle E. Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. Gene 2003;312:207-13
53. Available from: http://www.ncbi.nlm.nih.gov/SNP/ snp_ref.cgi?locusId=5447&chooseRs=all [Build 128, revised by May 25, 2006]
54. Flück CE, Miller WL. P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia. Curr Opin Pediatr 2006;18:435-41
55. Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005;76:729-49
56. Krone N, Dhir V, Ivison HE, Arlt W. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol 2007;66:162-72
57. Arlt W. P450 oxidoreductase deficiency and Andey-Bixler syndrome. Rev Endocr Metab Dis 2007;8:301-7
58. Adachi M, Tachibana K, Asakura Y, et al. A male patient presenting with major clinical symptoms of glucocorticoid deficiency and skeletal dysplasia, showing a steroid pattern compatible with 17alpha-hydroxylase/ 17,20-1yase deficiency, but without obvious CYP17 gene mutations. Endocr J 1999;46:285-92
59. Reardon W, Smith A, Honour JW, et al. Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 2000;37:26-32
60. Miller WL. Congenital adrenal hyperplasia. N Engl J Med 1986;314:1521-2
61. Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidngenesis with and without Antley-Bixler syndrome. Nature Genet 2004;36:228-50
62. Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004;363:2128-35
63. Fukami M, Horikawa R, Nagai T, et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrin Metab 2005;90:414-26
64. Haiman CA, Setiawan VW, Xia LY, et al. A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans. Cancer Res 2007;67:3565-8
65. Wu L, Gu J, Cui H, et al. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 2005;312:35-43
66. Hart SN, Li Y, Nakamoto K, et al. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 2007;22:322-6
67. Hart S, Wang S, Nakamoto K, et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genom 2008;18:11-24
68. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase, sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008;105:1733-8
69. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chemi 2006;281:35975-82
70. Dhir V, Ivison HE, Krone N, et al. Differential inhibition of CYPI7AI and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 2007;21:1958-68
71. Han JF, Wang SL, He XY, et al. Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity. Toxicol Sci 2006;91:42-8
72. Lu AY, Junk KW, Coon MJ. Resolution of the cytochrome P450-containing omega-hydroxylation system of liver microsomes into three components. J Biol Chemi 1969;244:3714-21
73. Misaka E, Nakanishi K. Studies on menadione reductase of baker's yeast. II. Inhibition of the enzyme activity by NAD and stimulation of that by p-chloromercuribenzoate. J Biochem 1965;58:1-6
74. Bachur NR GS, Gee MV, Kon H. NADPH cytochrome P450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979;76:954-7
75. Walton MI, Wolf CR, Workman P. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 1989;16:983-6
76. Saunders MP, Jaffar M, Patterson AV, Nolan J, et al. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 2000;59:993-6
77. Pattersoa AV, Barham HM, Chinje EC, et al. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 1995;72:1144-50
78. Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 1992;44:251-9
79. Elwell JH, Siim BG, Evans JW, Brown JM. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 1997;54:249-57
80. Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs 2000;9:2889-901
81. Wang SL, Han JF, He XY, et al. Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug Metab Dispos 2007;35:176-9
82. Benedetti A, Comporti M, Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta 1980;620:281-96
83. Saito M, Thomas CE, Aust SD. Paraquat and ferritin-dependent lipid peroxidation. J Free Rad Biol Med 1985;1:179-85